We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 05. | 장 마감 후 (AMC) | $0.18 | — | — | $647.61M | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $-6.25 | — | — | $651.3M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-2.99 | — | — | $2B |
Consensus PT $16.21 · 11 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 12. | Mizuho | — | 의견 유지 | Neutral → Neutral | — | Mizuho: Neutral |
| 2026. 05. 07. | Citigroup | — | 의견 유지 | Buy → Buy | — | Citigroup: Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-2.69 | — | — | $1.32B | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Stored first · Google News · Yahoo Finance (English)
Fortrea Holdings Hits Day High with 11.77% Surge in Strong Performance - Markets Mojo
Fortrea Holdings Hits Day High with 11.77% Surge in Strong Performance Markets Mojo
3 Overrated Stocks We Approach with Caution
Analysts Are Bullish on These Healthcare Stocks: Fortrea Holdings Inc. (FTRE), Cullinan Management (CGEM) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Fortrea Holdings Inc. (FTRE), Cullinan Management (CGEM) The Globe and Mail
Citi Maintains Fortrea Holdings(FTRE.US) With Buy Rating - 富途牛牛
Citi Maintains Fortrea Holdings(FTRE.US) With Buy Rating 富途牛牛
Fortrea Gains Attention As Drug Development Services Sector Evolves - Kalkine Media
Fortrea Gains Attention As Drug Development Services Sector Evolves Kalkine Media
Spotting Winners: Fortrea (NASDAQ:FTRE) And Drug Development Inputs & Services Stocks In Q1 - Yahoo Finance
Spotting Winners: Fortrea (NASDAQ:FTRE) And Drug Development Inputs & Services Stocks In Q1 Yahoo Finance